Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 4, 2006, Pages 467-473

  Liu, Feng ^a   Minami, Haruka ^a   Silva, Raul R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADHD; Chemistry; Dexmethylphenidate; Pharmacokinetics; Receptor binding; Toxicology

Indexed keywords

CENTRAL STIMULANT AGENT; COCAINE; DEXMETHYLPHENIDATE; FOCALIN XR; LEVO THREO METHYLPHENIDATE; METHYLPHENIDATE; PLACEBO; RITALINIC ACID; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENTERIC COATED TABLET; ESTERIFICATION; FOOD; FOOD DRUG INTERACTION; HUMAN; NONHUMAN; PHARMACODYNAMICS; RACEMIC MIXTURE; REVIEW; SELF ESTEEM; SIDE EFFECT; SOCIAL STATUS;

EID: 33847290883     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.4.467     Document Type: Review

References (61)

1. Anonymous. 2002. Dexmethylphenidate-Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride. Drugs in R&D, 3:279-82.
2. Arnold LE, Lindsay RL, Conners CK. et al. 2004. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 14:542-54.
3. Barkley RA, 1990. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry, 63(Suppl 12):10-15.
4. Biederman J, Faraone S, Milberger S, et al. 1996. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry, 53:437-46.
5. Bradley C. 1937. The behavior of children receiving benzedrine. Am J Psychiatry, 94:577-85.
6. Davids E, Zhang K, Kula NS, et al. 2002a. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J Pharmacol Exp Ther, 301:1097-102.
7. Ding YS, Fowler JS, Volkow ND, et al. 1997. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology, 131:71-8.
8. Ding YS, Fowler JS, Volkow ND, et al. 1995. Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J Nucl Med, 36:2298-305.
9. Ding YS, Gatley SJ, Thanos PK, et al. 2004. Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Synapse, 53:168-75.
10. Dulcan M. 1997. Work group on quality issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 36:S85-121.
11. Fowler JS, Volkow ND, Logan J et al. 1998. Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. Synapse, 28:111-16.
12. Gatley SJ, Ding YS, Volkow ND, et al. 1995. Binding of d-threo-[11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Eur J Pharmacol, 281:141-9.
13. Gatley SJ, Pan D, Chen R, et al. 1996. Affinity of methylphenidate derivatives for dopamine, Norepinephrine and serotonin transporters. Life Sci, 58:231-9.
14. Gatley SJ, Volkow ND, Gifford AN, et al. 1999. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology, 146:93-100.
15. Goldman LS, Genel M, Bezman RJ, et al, 1998: Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA, 279:1100-7.
16. Greenhill LL, Pliszka S, Dulcan MK, et al. 2002. American Academy of Child and Adolescent Psychiatry. Practice parameter for use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry, 41(Suppl 2):26-49S.
17. Greenhill L, et al. 2005. Extended-release dexmethylphenidate in child and adolescent with ADHD. 158th Annual Meeting of the American Psychiatric Association. May 21-25, 2005; Atlanta, GA, USA.
18. Guevara J, Lozano P, Wickizer et al. 2002. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics, 109:733-9.
19. Hubbard JW, Srinivas NR, Quinn D, et al. 1989. Enantioselective aspects of the disposition of d.l-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. J Pharma Science, 78:944-7.
20. Keating GM, Figgitt DP. 2002. Dexmethylphenidate. Drugs, 62:1899-904; discussion 1905-8.
21. Kilbourn MR. 2004. Long-term reproducibility of in vivo measures of specific binding of radioligands in rat brain. Nucl Med Biol, 31:591-5.
22. Kimko HC, Cross JT, Abernethy DR, et al. 1999. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet, 37:457-70.
23. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. 2000. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett, 285:107-10.
24. Lesesne CA, Visser SN, White CP 2003: Attention-deficit/hyperactivity disorder in school-aged children: association with maternal mental health and use of health care resources. Pediatrics, 111:1232-7.
25. Lim HK, Hubbard JW, Midha KK. 1986. Development of enantioselective gas chromatographic quantitation assay for d.l-threo-methylphenidate in biological fluids. J Chromatography, A 378:109-23.
26. Logan J, Fowler JS, Volkow ND, et al. 2001. A strategy for removing the bias in the graphical analysis method. J Cereb Blood Flow Metab, 21:307-20.
27. Logan J, Fowler JS, Volkow ND, et al. 1996. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab, 16:834-40.
28. Markowitz JS, Straughn AB, Patrick KS, 2003. Advances in the pharmacotherapy of attention-deficit-hyper activity disorder: focus on methylphenidate formulations. Pharmacotherapy, 23:1281-99.
29. Markowitz JS, DeVane CL, Pestreich L, et al. 2005. Differentiation of d,L- and dl-methylphenidate through in vitro pharmacological screening. Proceedings of Abstracts from Oral and Poster Presentations, NCDEU-NIMH 45th Annual Meeting; Boca Raton, FL, USA. p 186.
30. Modi NB, Wang B, Noveck RJ, et al. 2000. Gupta SK. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol, 40:1141-9.
31. Novartis Pharmaceuticals Corporation. 2005. PDR Focalin XR, Insert package, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
32. Patrick KS, Caldwell RW, Ferris RM, et al. 1987. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther, 241:152-8.
33. Patrick KS, Gonzalez MA, Straughn AB, et al. 2005. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Deliv, 2:121-43.
34. Patrick KS, Kilts CD, Breese GR. 1981. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem, 29:1237-40.
35. Quinn DM. 2000. Methylphenidate: the role of d-isomer. In Ritalin. Theory and practice. 2nd ed. New York: MA Liberty Publishers Larchmont. p 369-74.
36. Quinn D, Wigal S, Swanson J, et al. 2004. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 43:1422-9.
37. Scheffler MR, Teo S, Stirling D, et al. 2003. Multiple dosing of dexmethylphenidate HLC (d-MPH) does not result in accumulation or interconversion tp l-methylphenidate HCL in male and female children. Clin Pharmacol Ther, II:27.
38. Silva R, Tilker HA, Cecil JT, et al. 2004. Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 14:555-63.
39. Silva, RR, Muniz, R, Pestreich, L, et al. 2005 Performance improvement in school children with ADHD receiving once-daily dexmethylphenidate. Scientific Proceedings from the American Academy of Child and Adolescent Psychiatry 52nd Annual Meeting. Toronto, Canada. p 121.
40. Silva RR, Muniz R, Pestreich L, et al. 2006. Efficacy and duration of effect of extended-release dexmethylphenidate vs placebo in school children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. In press.
41. Srinivas NR, Hubbard JW, Quinn D, et al. 1992. Enantioselective pharmacokinetics and pharmacodynamics of d, l-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther, 52:561-8.
42. Srinivas NR, Quinn D, Hubbard JW, et al. 1987. Stereoselective disposition of methylphenidate in children with attention-deficit disorder. J Pharmacol Exp Ther, 241:300-6.
43. Srinivas NR, Hubbard JW, Koechinsk ED, et al. 1993. Enantioselective pharmacokinetics of d.l-threo-methylphenidate in humans. Pharm Res, 10:14-21.
44. Sun Z, Murry DJ, Sanghani SP, et al. 2004. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther, 310:469-76.
45. Swanson JM, Lerner M, Wigal T, et al. 2002. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord, 6(Suppl 1):S73-88.
46. Teo SK, Stirling D, Thomas S, et al. 2002. A 90-day oral gavage toxicity study of D-methylphenidate and D, L-methylphenidate in Sprague-Dawley rats. Toxicology, 179:183-96.
47. Teo SK, San RH, Wagner VO, et al. 2003a. D-Methylphenidate is non-genotoxic in in vitro and in vivo assays. Mutation Res, 537:67-79.
48. Teo SK, Scheffler MR, Wu A, et al. 2004. A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects. J Clin Pharmacol, 44:173-8.
49. Teo SK, Stirling DI, Hoberman AM, et al. 2003b. D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol, 68:162-71.
50. Teo SK, Stirling DI, Thomas SD, et al. 2003c. A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in beagle dogs. Inter J Toxicol, 22:215-26.
51. Teo SK, Stirling DI, Thomas SD, et al. 2002. The perinatal and postnatal toxicity of D-methylphenidate and D,L-methylphenidate in rats. Reprod Toxicol, 6:353-66.
52. Teo SK, Stirling DI, Thomas SD, et al. 2003d. Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats. Pharmacol Biochem Behav, 74:747-54.
53. Volkow ND, Chang L, Wang GJ, et al. 2001a. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neuroscience, 21:9414-8.
54. Volkow ND, Chang L, Wang GJ, et al. 2001b. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry, 158:377-82.
55. Volkow ND, Ding YS, Fowler JS, et al. 1996. Dopamine transporters decrease with age. J Nucl Med, 37:554-9.
56. Volkow ND, Ding YS, Fowler JS, et al. 1995. A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med, 36:2162-8.
57. Volkow ND, Fowler JS, Wang G, et al. 2002. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord, 6(Suppl):S31-43.
58. Wang GJ, Volkow ND, Fowler JS, et al. 1995. Comparison of two pet radioligands for imaging extrastriatal dopamine transporters in human brain. Life Sci, 57:187-91.
59. Weiss M, Wasdell M, Patin J. 2004. A posthoc analysis of d-threo-methylphenidate hydrochloride (focalin) vs d,l-threo-methylphenidae hydrochloride (ritalin). J Am Acad Child Adolesc Psychiatry, 43:1415-21.
60. Wigal S, Swanson JM, Feifel D, et al. 2004. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 43:1406-14.
61. Wilens TE, Faraone SV, Biederman J. 2004. Attention-deficit/ hyperactivity disorder in adults. JAMA, 292:619-23.